All In Biotech

Drug Trial Radar · NCT06066645

Travoprost Intraocular Implant + iStent Infinite

Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite in Subjects With Open-angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 14, 2023

Primary completion

May 2027

Study completion Feb 2028

Sponsor

Lead sponsor
Glaukos CorporationIndustry
Sponsor type
Industry
First posted
Oct 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.

Conditions

  • Glaucoma, Open-Angle

Interventions

  • Travoprost Intraocular ImplantDrug

    anchored intracameral implant containing travoprost

  • iStent infiniteDevice

    Successful iStent infinite surgery

  • Sham procedureOther

    Sham procedure (to mimic placement of an iStent infinite)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change from baseline in mean diurnal intraocular pressure (IOP)Time frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Glaukos Clinical Study Site

    Oklahoma City, Oklahoma · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.